Definitive Contract HHSN261201600051C

<p>This is a small business set-aside contract awarded by the National Cancer Institute (NCI), a civilian agency, to Dxterity Diagnostics Incorporated. The contract is for the development of a blood test to predict radiation toxicity in patients undergoing radiation therapy, as part of the Small Business Innovation Research (SBIR) program. The definitive, firm-fixed price contract has a ceiling value of $280,005.00 and a performance period ending on March 31, 2015.</p>

<p>This is a $1,999,984.00 Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency, to Diacarta, Inc. The contract is for the TOPIC 345 - SBIR PHASE II: RADTOX - MEASURING RADIATION TOXICITY USING CIRCULATING DNA project, which aims to develop a method for measuring radiation toxicity using circulating DNA. The contract has a Firm Fixed Price pricing type and is set to be completed by March 15, 2023.</p>

This is a Small Business Set-Aside contract awarded by the National Cancer Institute (NCI), a civilian agency, to DiaCarta L.L.C., a minority-owned, for-profit limited liability company. The $299,698.00 firm-fixed-price contract is for a Small Business Technology Transfer (STTR) Phase I research project to develop &quot;Predictive Biomarkers of Adverse Reactions to Radiation Treatment&quot; over a period from September 19, 2016 to June 18, 2017. The contract does not appear to be associated with...

This contract was awarded by the National Institutes of Health (NIH), which is part of the U.S. Department of Health and Human Services (HHS). It is a Small Business Innovation Research (SBIR) Phase II contract awarded to Mira DX Inc., a Woman-Owned Small Business (WOSB). The contract has a potential value of $1,999,999.00 and is a Firm Fixed Price contract. The contract was awarded under Topic 338 of the SBIR program, which is focused on &quot;Defining Normal Tissue and Tumor Biomarkers of...

This is a Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Radiopharmaceutical Imaging and Dosimetry, LLC, doing business as Radiopharmaceutical Imaging &amp; Dosimetry LLC, a small business. The contract, valued at $299,275, is for a Small Business Innovation Research (SBIR) Phase I project to optimize targeted radionuclide therapy for metastatic liver cancer patients. This contract supports the NCI's broader...

This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), part of the Department of Health and Human Services' National Institutes of Health, to Radiomedix, Inc., a small disadvantaged business. The contract, valued at $1,994,002.00, is for the development of targeted radionuclide therapy using 212Pb-octreotate analogs for the treatment of neuroendocrine tumors. The contract was awarded on September 18, 2018 and has a completion date of...

This is a $1,994,911 firm fixed price contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Earlydiagnostics Inc., doing business as Earlydx. The contract is part of the NCI's Small Business Innovation Research (SBIR) program and has a total small business set-aside designation. The contract supports Earlydx's research and development of a cloud-based liquid-biopsy platform for the Cancer Research Data Commons. Earlydx is a for-profit...

This is a $396,190 firm fixed price Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (part of the National Institutes of Health) to Tetraimaging LLC, a small disadvantaged business, to develop ultra-fast dose rate (FLASH) radiation detectors and safety systems. The contract was awarded on September 16, 2022 and is set to complete by December 15, 2023. The original solicitation, PHS-2022-1, announced by the NIH and CDC, sought small business...

The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a Small Business Innovation Research (SBIR) Phase I contract to Radiopharmaceutical Imaging And Dosimetry, LLC (doing business as Radiopharmaceutical Imaging &amp; Dosimetry LLC), a for-profit limited liability company. The $299,466.00 firm-fixed-price contract, which was set aside for small businesses, is for the development of user-friendly, platform-independent software to incorporate...

This is a $454,997 fixed-price Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH), to Ambay Immune Sensors And Controls, LLC, a woman-owned small business. The contract was awarded under the FY20 SBIR Phase I solicitation and is for the development of a &quot;non-invasive, novel test to monitor biological response to radiotherapy&quot; under Topic #400 - AMBAY RADI-SENSE. The contract...